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Abstract
Objective: Elevated liver enzymes have been recognized as a predictor 
for the development of metabolic syndrome and type 2 diabetes mellitus in 
patients with nonalcoholic fatty liver disease (NAFLD). However, the asso-
ciation of insulin resistance with alanine aminotransferase (ALT) activity 
remains largely unknown.
Patients and Methods: A total of 454 subjects attending the health exam-
ination center were enrolled from September 2005 through December 
2006. Of them, 203 patients (male/female, 113/90; mean age, 50.9 years) 
were identified to have NAFLD. Their insulin resistance index was deter-
mined using the homeostasis model assessment (HOMA-IR). Elevated ALT 
level was defined as > 30 IU/L for male and > 19 IU/L for female subjects 
according to the new cut-off values.
Results: There were 113 subjects in the elevated ALT group and 90 in the 
normal ALT group. Age, gender and the prevalence of diabetes mellitus, 
hypertension and smoking history were comparable between these two 
groups. The elevated ALT group had higher readings for body mass index, 
triglyceride, total cholesterol, low-density lipoprotein cholesterol, insulin and 
HOMA-IR than the normal ALT group using univariate analyses. Multivariate 
logistic regression analyses showed that only log(HOMA-IR) was positively 
associated with elevated ALT level in the NAFLD patients (adjusted odds 
ratio, 5.04; 95% confidence interval, 1.56–16.27).
Conclusion: Our data showed that there was an association between 
insulin resistance and serum ALT levels in NAFLD patients, independent of 
other metabolic factors. However, further longitudinal studies are needed 
to clarify the causal relationship between insulin resistance and increased 
ALT activity in patients with NAFLD. [Tzu Chi Med J 2008;20(4):275–279]
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD), already the 
most common liver disease in the United States, can 
be expected to increase parallel with the epidemics 
of obesity and type 2 diabetes mellitus [1]. The term 
refers to a spectrum of disorders from simple steatosis 
to more severe manifestations including steatohepa-
titis, fibrosis and cirrhosis [2]. In addition, subjects 
with NAFLD have been reported to have high preva-
lence of metabolic syndromes and high risk of cardio-
vascular diseases [3–6]. Therefore, NAFLD is emerging 
as a global health problem.
The pathogenesis of NAFLD has been proposed to 
result from two physiologic events [7]. The first event 
is thought to be insulin resistance, leading to the ac-
cumulation of triglycerides in hepatocytes and sub-
sequent lipid peroxidation. The second event includes 
increased oxidative stress, cytokine release and, ulti-
mately, Fas ligand-mediated liver injury. Serum alanine 
aminotransferase (ALT) level is recognized as a clinical 
marker of liver injury and may reflect the outcome of 
the second event in the pathogenesis of NAFLD [8]. 
Furthermore, increased ALT activity has been recog-
nized as a predictor of the development of diabetes 
and metabolic syndromes in NAFLD patients [9,10]. 
However, the association of increased ALT activity 
with insulin resistance or metabolic factors in NAFLD 
patients remains unclear. In this cross-sectional study, 
we explored demographic and metabolic factors asso-
ciated with increased ALT activity in NAFLD patients.
2. Materials and methods
2.1. Subjects and methods
A total of 454 subjects attending the health examina-
tion center at the Buddhist Tzu Chi General Hospital 
in Taipei, Taiwan with informed consent were enrolled 
from September 2005 through December 2006. Of 
them, 203 subjects who fulfilled the diagnostic criteria 
of NAFLD were included in the study. The diagnostic 
criteria of NAFLD included no excessive alcohol intake 
(< 140 g/week), no chronic viral hepatitis (negative for 
hepatitis B surface antigen and antibody against hep-
atitis C virus), no known etiologies of liver diseases, 
and the presence of fatty liver on liver ultrasound 
examinations [11]. Age, gender, body weight, body 
height, body mass index (BMI), and waist circumference 
were recorded. Biochemical tests including fasting 
plasma glucose, ALT, aspartate aminotransferase (AST), 
triglyceride, total cholesterol, high-density lipoprotein 
cholesterol (HDL-C) and low-density lipoprotein cho-
lesterol (LDL-C) were determined using standard lab-
oratory procedures. Serum insulin levels were assessed 
using an enzyme-linked immunoassay (Bayer Corp., 
Tarrytown, NY, USA). Insulin resistance (IR) was calcu-
lated using the homeostasis model assessment for 
insulin resistance (HOMA-IR) index. HOMA-IR = fasting 
insulin (mU/L) × fasting glucose (mg/dL) × 0.05551/22.5 
[12]. Those with diabetes mellitus were defined as 
having previous diabetic history or fasting plasma 
glucose level > 126 mg/dL. Elevated ALT levels were 
defined as > 30 IU/L for male subjects and > 19 IU/L 
for female subjects according to the new cut-off 
values [13].
2.2. Ultrasound examination
A GE LOGIO 5 Pro Ultrasound system (GE Medical 
Systems, Seoul, Korea) with a 4-MHz electronic probe 
was used to examine the livers. The presence of fatty 
liver was assessed on the basis of ultrasonographic 
findings of a bright liver, increased echogenicity with 
evident contrast between the liver and kidney, vascular 
blurring and deep attenuation of the ultrasound signal 
as previously described [14,15].
2.3. Ethical considerations
The study was conducted in accordance with the 
principles of the 1975 Declaration of Helsinki and 
approved by the Ethics Committee of the Buddhist Tzu 
Chi General Hospital in Taipei, Taiwan. Serum sam-
ples were obtained after receiving informed consent 
from each subject.
2.4. Statistical analysis
Data were expressed as mean ± standard deviation. 
HOMA-IR distributed as a screw pattern, thus was log-
transformed for subsequent analysis. χ2 and t tests 
were used to analyze categorical and continuous 
variables, respectively. Statistical analyses were per-
formed using Stata version 8.0 (Stata Corp., College 
Station, TX, USA) and all tests were two-sided. A value 
of p < 0.05 was considered statistically significant.
3. Results
3.1. Study population and demographic data
A total of 203 NAFLD patients (men/women, 113/90; 
mean age, 50.9 years) were included for final analysis. 
The prevalence of metabolic syndromes according to 
the modified Adult Treatment Panel III diagnostic cri-
teria was 32% in these NAFLD patients. There were 
113 subjects in the elevated ALT group and 90 in the 
normal ALT group. The demographic and metabolic 
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features of the two groups are shown in Table 1. These 
two groups of patients were comparable in terms of 
age, gender and the prevalence of diabetes mellitus, 
which are the major confounding factors of insulin 
resistance. In addition, the prevalence of hypertension 
and smoking history did not differ between the patients 
with and without ALT elevation.
3.2. Factors associated with elevated 
serum ALT levels
By univariate analyses, the prevalence of metabolic 
syndromes, serum insulin levels and HOMA-IR were 
significantly higher in the elevated ALT group than in 
the normal ALT group. Regarding the lipid profile, 
subjects with elevated ALT levels had increased 
serum triglyceride, total cholesterol and LDL-C levels 
compared to those with normal ALT levels. In addi-
tion, NAFLD patients with elevated ALT levels had 
higher BMI than those with normal ALT levels. In con-
trast, fasting plasma glucose levels, serum HDL-C 
levels and waist circumference were comparable be-
tween the two groups of patients. Using multiple lo-
gistic regression analyses, the factors associated with 
ALT elevation in the NAFLD patients are shown in 
Table 2. The model was adjusted for BMI, triglyceride, 
total cholesterol, LDL-C and log(HOMA-IR). In addi-
tion, the association holds true even after excluding 
patients with diabetes mellitus for analyses. Our data 
showed that only log(HOMA-IR) was positively associ-
ated with elevated ALT levels in patients with NAFLD 
(adjusted odds ratio, 5.04; 95% confidence interval, 
1.56–16.27).
4. Discussion
Little is known about the association of insulin resis-
tance with serum ALT levels except in special groups 
such as obese subjects and patients with HIV lipodys-
trophy [16–19]. Researchers in a previous study showed 
that elevated ALT levels and fatty livers were inde-
pendently associated with increased risk of metabolic 
syndromes [20]. Therefore, it has been speculated that 
insulin resistance may have dual effects on inducing 
fat accumulation in liver cells and initiating the inflam-
matory cascade by which liver injury is caused. However, 
the authors failed to provide direct evidence to prove 
the positive association between insulin resistance and 
elevated serum ALT levels. In our study, we found 
that elevated ALT levels were significantly associated 
with insulin resistance and the components of meta-
bolic syndrome in NAFLD patients using univariate 
Table 1 — Comparisons of demographic and metabolic features between nonalcoholic fatty liver disease patients 
with and without ALT elevation*
Features Elevated ALT group (N = 113) Normal ALT group† (N = 90) p
Age (yr) 50.8 ± 1.0 51.0 ± 1.4 0.89
Male 57 (50) 56 (62) 0.09
Body mass index (kg/m2) 26.0 ± 0.3 24.8 ± 0.4 0.02
Waist circumference (cm) 85.3 ± 0.9 84.4 ± 1.2 0.54
Fasting blood glucose (mg/dL) 105.9 ± 3.1 100.0 ± 3.3 0.20
Insulin (mU/L) 10.7 ± 0.7 8.0 ± 0.6 < 0.01
HOMA-IR 2.8 ± 0.2 2.1 ± 0.2 0.02
AST (IU/L) 29.7 ± 1.5 20.2 ± 1.2 < 0.01
ALT (IU/L) 42.3 ± 2.2 19.6 ± 0.6 < 0.01
Triglyceride (mg/dL) 168.6 ± 10.7 128.4 ± 8.0 < 0.01
Total cholesterol (mg/dL) 203.1 ± 4.0 186.1 ± 4.0 < 0.01
LDL-C (mg/dL) 140.1 ± 3.8  127 ± 4.0 0.01
HDL-C (mg/dL) 50.6 ± 1.2 51.8 ± 1.7 0.56
Diabetes mellitus 17 (15.04) 9 (10.00) 0.29
Hypertension 17 (15.18) 18 (20.00) 0.37
Smoking habit 16 (14.16) 15 (16.67) 0.62
Metabolic syndrome 44 (38.94) 21 (23.33) 0.02
*Data presented as mean ± standard deviation or n (%);†normal ALT level is < 30 U/L in males and < 19 U/L in females. ALT = alanine aminotransferase; 
HOMA-IR = homeostasis model assessment-insulin resistance; AST = aspartate aminotransferase; LDL-C = low-density lipoprotein cholesterol; 
HDL-C = high-density lipoprotein cholesterol.
Table 2 — Factors associated with ALT elevation in 
nonalcoholic fatty liver disease patients by multiple 
logistic regression analyses*†
 Adjusted OR (95%CI)
Body mass index (kg/m2) 1.02 (0.93–1.12)
Total cholesterol (mg/dL) 1.01 (0.99–1.04)
Triglyceride (mg/dL) 1.00 (1.00–1.01)
Log(HOMA-IR) 5.04 (1.56–16.27)‡
LDL-C (mg/dL) 1.00 (0.97–1.02)
*Model is adjusted for body mass index, total cholesterol, triglycer-
ide, log(HOMA-IR) and LDL-C; †normal ALT level is < 30 U/L in males 
and < 19 U/L in females; ‡p < 0.05. ALT = alanine aminotransferase; 
HOMA-IR = homeostasis model assessment-insulin resistance; LDL-C = 
low-density lipoprotein cholesterol.
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analysis. In addition, multivariate logistic regression 
analysis showed that insulin resistance was the only 
factor that positively correlated with increased ALT 
activity after adjustment of several demographic and 
metabolic variables. It is generally believed that insulin 
resistance plays a central role in the pathogenesis of 
NAFLD. Our data further suggested that insulin re-
sistance may be directly associated with the inflamma-
tory process of the liver in NAFLD patients. In addition, 
a recent case-control study indicated that pioglitazone, 
an insulin sensitizer, normalized liver aminotransferase 
and improved histological findings especially in the 
grade of necroinflammation in subjects with nonal-
coholic steatohepatitis (NASH) [21]. Taking these lines 
of evidence together, insulin resistance also plays an 
important role in the initiation of the inflammatory 
cascade (second event) to incite the aggressive form 
of NAFLD called NASH [22].
Although several studies have indicated the impact 
of elevated serum ALT levels on the risk of the sub-
sequent occurrence of diabetes mellitus, metabolic 
syndromes and coronary heart diseases [23–25], the 
mechanisms to explain these associations remain 
controversial. It is known that insulin resistance plays 
a key role in the development of diabetes mellitus 
and metabolic syndromes. However, whether insulin 
resistance could explain the relationship between in-
creased ALT activity and diabetes mellitus as well as 
metabolic syndromes awaits further examinations. 
A community-based study was conducted in Taiwan 
to determine the prevalence and risk factors of NAFLD 
in the general population [26]. The results showed 
that NAFLD patients with elevated ALT levels did not 
differ from those with normal ALT levels in the preva-
lence of each metabolic derangement. Thus, serum 
ALT level might not be a good predictor of metabolic 
abnormalities in NAFLD patients. On the contrary, 
another group of researchers investigated the relative 
contribution of metabolic syndromes and insulin re-
sistance to increased ALT activity in NAFLD patients, 
and defined the number of metabolic syndromes as 
central obesity, plus 0 to 4, according to the number 
of other four metabolic syndrome components by the 
new International Diabetes Federation (IDF) definition 
[27]. They found that the number of metabolic syn-
drome components, BMI, hs-CRP and insulin resistance 
were predictors of increased ALT activity in patients 
with NAFLD [28]. In this study, our data further proved 
the association of insulin resistance with increased 
ALT levels in NAFLD patients, independent of other 
metabolic factors which could confound the value of 
insulin resistance, suggesting that increased ALT levels 
might serve as a surrogate marker of insulin resistance 
and reflect the increased risk of diabetes mellitus, 
metabolic syndromes or even cardiovascular diseases. 
Researchers in two recent studies also found an early 
association of ALT with insulin resistance in women 
[29,30]. Thus, NAFLD patients with increased ALT 
activity deserve aggressive treatment of coexisting 
metabolic disorders and strict lifestyle modification 
to improve insulin sensitivity and reduce the risk of 
cardiovascular diseases.
Age, gender, and the presence of diabetes mellitus 
are the major confounding factors of insulin resistance 
[31]. We enrolled consecutive subjects from a health 
examination center with informed consent to avoid 
selection bias, and our results showed that the afore-
mentioned factors were comparable between the 
NAFLD patients with and without ALT elevation. Ac-
cordingly, we objectively demonstrated the correlation 
between insulin resistance and increased ALT activity 
in NAFLD patients. However, a number of potential 
limitations should be considered. For example, the 
case number in this cohort was relatively small, and the 
cross-sectional study design did not show the causal 
relationship. Therefore, further large-scale and longi-
tudinal studies are needed to clarify the causal rela-
tionship between insulin resistance and increased 
ALT activity in patients with NAFLD.
In summary, our findings suggested that insulin 
resistance is associated with increased ALT activity in 
patients with NAFLD, and is independent of other met-
abolic factors. These observations will lay the ground-
work for further studies to clarify the association of 
insulin resistance with liver inflammation in the patho-
genesis of NAFLD. Nevertheless, the link between 
insulin resistance and liver damage needs prospective 
and mechanistic studies.
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